Toxic in Medical Technology

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

... lead molecules that block the activity of the toxic oligomeric form of Abeta protein that interferes ... of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline ... other degenerative diseases of the human brain. toxic proteins play a crucial role in a large class of ...

Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation

... of PBT2 (Prana Biotechnology), which reduces the toxic form of amyloid by preventing the interaction of ... a tau aggregation inhibitor that targets toxic tau aggregates, or "tangles." Tangles of tau in ... if its ability to lower the amount of toxic beta-amyloid would slow or stop the course of the ...

EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435

... chemicals are some of the most toxic chemicals known. The CALUX(R) by XDS (Chemical ... rapidly detect and quantify these ubiquitous and toxic environmental contaminants. "This approval ... clients and safeguard the environment from these toxic contaminants." Research Institutes Worldwide ...

The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh

... platform. "Our approach is to target the toxic proteins that build up in the brains of elderly ... suggests that blocking this protein and its toxic actions early on in the course of the ... of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline ...

Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain

... as a simple injection under the skin, similar to a flu shot, and is not toxic as chemotherapies are. The most recent data provides an update for the ... own immune cells and own tumor material, and does not cause the kinds of toxic side effects seen with typical cancer treatments. DCVax-Brain is helping ...

PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S.

... About RenalGuard RenalGuard is designed to reduce the potentially toxic effects that contrast media can have on the kidneys when it is ... void the contrast media, thereby reducing its overall resident time and toxic effects in the kidney. Contrast-Induced Nephropathy CIN is a major and ...

CEL-SCI Corporation Releases Letter to Shareholders

... 2) Multikine so far has been shown to be safe, and well tolerated. It is toxic only to cancer cells. Our goal is to receive world-wide marketing ... that it works on multiple fronts in the battle against cancer, and it is toxic only to cancer cells. Multikine represents a new class of immunotherapy ...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

... in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. Access has previously announced that it ...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

... heart, lungs, skin, joints and blood. No new treatments for lupus have been approved in almost 50 years and many currently used treatments are as toxic as the disease itself. Lupus is a leading cause of premature cardiovascular disease, kidney disease and stroke among young women. About ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... that to happen, we need to get much better at early detection and diagnosis of Alzheimer's. Phase III Alzheimer's Drug Raises Level of a toxic Protein Recent evidence suggests that the drug Dimebon may improve cognitive function in people with mild to moderate Alzheimer's, but how ...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

... rejection and results in airflow obstruction. The disease is also a factor in other lung diseases such as collagen vascular diseases, inhalation of toxic fumes, and respiratory tract infections. Bronchiolitis obliterans affects approximately 60,000 patients worldwide, and once it develops, most ...

AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

... which mutations in the PBGD gene result in insufficient activity of a protein necessary for the synthesis of heme. This leads to an accumulation of toxic intermediate metabolites resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric, neurologic illnesses, and ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required. About BioVex BioVex is a privately held biotechnology company based in Woburn, ...

Tris Pharma Announces Acceptance of Its First Two NDAs

... those used for the older products. To manufacture the cardiovascular drug, the company uses a safe water-based process, replacing the need for the toxic organic solvents used in the older products. This new aqueous solvent, coupled with Tris' patent-pending manufacturing process, also improves product ...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

... Posterboard Number : A452 - Program Number: 4919 Sirion Therapeutics Poster Presentations Featuring Retinal Research Accumulation of toxic Retinal Fluorophores in Various Degenerative Retinal Diseases Session Date/Start Time: Wednesday May 6, 8:30-10:15 am Posterboard Number: ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score ...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

... yielding a significant reduction of viral RNA synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology studies indicate that the compound is well tolerated and has ...

Nation's Laboratory Response Network Marks First Decade of Protecting Public Health

... of bioterrorism, the Laboratory Response Network has evolved to become the nation's laboratory resource for response to emerging infectious diseases, toxic spills, natural disasters, chemical terrorism and other public health threats. LRN member laboratories conduct confirmatory testing of specimens ...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... with a safety issue identified in Vancocin's labeling and by its own 2008 advisory committee - the potential for systemic absorption of the drug at toxic levels and the need for pharmacokinetic (PK) testing to address that safety issue - OGD again turned away from patients with CDI. Instead, they ...

Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results

... and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis. ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score ...

Cancer Research 'David' Hopes to Slay 'Cancer Goliath'

... Foundation), a 501(c)(3) non-profit cancer research organization in Phoenix, AZ, was established eleven (11) years ago to find effective but less toxic forms of cancer treatment. They have now confirmed an anti-cancer material which they gave the laboratory name, Protein-B(LPN). Protein-B(LPN) ...

For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold

... end-stage renal disease -- treatment in the form of regular dialysis (or hemodialysis) is needed to replace the kidney's job of ridding the body of toxic waste products to maintain fluid, electrolyte and acid-base balance. A machine is used to filter blood outside one's body, allowing blood to flow, a ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. About Access: Access ...

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease

... Protein). The stimulation of the alpha-secretase pathway being to the detriment of Abeta amyloid peptide production, EHT 0202 potentially reduces toxic Abeta plaque formation [1]. Phase I studies demonstrated good tolerability of EHT 0202 in both young and aged healthy volunteers; importantly, ...

Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea

... in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. Access recently presented data from the ...

Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival

... that patient throughout the treatment period. DCVax(R)-Brain is administered as a simple injection under the skin, similar to a flu shot, and is not toxic as most chemotherapies are. DCVax(R)-Brain is now in a large Phase II clinical trial which is currently enrolling patients at 11 medical ...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

... during a median five cycles of therapy. "AML is a difficult-to-treat blood cancer, particularly in elderly patients who cannot endure the toxic side effects of standard induction chemotherapy," said lead investigator, Amanda Cashen, MD, assistant professor, Washington University School of ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... featured in two oral sessions at ASH - Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can damage key organs - New long-term data from major independent breast cancer trial at SABCS to report on optimal post-surgery ...

Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis

... 48 patients with moderate to severe alcoholic hepatitis. Patients were either given a placebo or etanercept, a compound which blocks the effects of toxic cytokines. Etanercept is approved for treatment of inflammatory arthritis and is under investigation for effectiveness in treating other inflammatory ...

GEN Reports on the Trend Toward Predictive Toxicogenomics

... unravel the cellular machinery underlying toxicity responses, which then are tested more thoroughly using other assays. Novartis is employing known toxic compounds to develop the techniques to understand the mechanistic actions of toxicity. Such screening led to the recent validation of biomarkers for ...

Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial

... of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive and toxic antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every ...

Aiming at Multiple Alzheimer's Proteins May be Key to Success

... for single molecules that will bind to both proteins and possibly other Alzheimer's-related proteins before they begin to misfold and start their toxic buildup. "Right now, we're treating the symptoms of the disease -- only slowing cognitive decline and memory loss in patients," says Dr. Weaver. "My ...

BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

... very limited with only one chemotherapeutic agent approved for the treatment of metastatic prostate cancer that extends survival by ~ 2 months, with toxic side effects. All other therapies for this stage of disseminated prostate cancer are palliative and do not prolong survival. Thus, improved therapies ...

Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

... very limited with only one chemotherapeutic agent approved for the treatment of metastatic prostate cancer that extends survival by - 2 months, with toxic side effects. All other therapies for this stage of disseminated prostate cancer are palliative and do not prolong survival. Thus, improved therapies ...

Eating Walnuts Slows Cancer Growth, Laboratory Study Finds

... at the impact of walnut consumption on cancer growth. "It's always very good to find something that will slow the growth of tumors without being toxic chemotherapy," said Hardman, who has spent 15 years studying the role of diet in cancer. Walnuts have at least three components that could account ...

deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer

... in the United States during 2008 and that 14,100 people will die of the disease. Bladder cancer has been linked to exposure to various types of toxic substances such as cigarette smoke and industrial chemicals. Although it has been known for some time that genetic factors also play a significant ...

Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate

... government, strengthen the science base in toxicology, develop and validate improved testing methods, and provide information about potentially toxic chemicals to health, regulatory, and research agencies, scientific and medical communities, and the public. The NTP is headquartered at the NIEHS, ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... Data collected in the animal studies conducted with CEL-2000 demonstrate it is effective with fewer and smaller doses. It is also potentially less toxic and more disease specific therapy. Finally, CEL-2000 could also be useful for patients who are not able to take or who may be unresponsive to ...